Does Rallies show 13F holders for TRIB?

Yes. Rallies tracks hedge fund and 13F ownership data for TRIB, including fund names, share counts, latest tracked quarter, and position changes when available.

Is TRIB research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TRIB. It does not provide personalized investment advice.

TRIB (Trinity Biotech plc) Stock Analysis - Hedge Fund Holdings

Trinity Biotech plc (TRIB) is a publicly traded Healthcare sector company. As of May 21, 2026, TRIB trades at $0.59 with a market cap of $11.54M and a P/E ratio of 0.00. TRIB moved +6.65% today. Year to date, TRIB is -20.85%; over the trailing twelve months it is -25.11%. Its 52-week range spans $0.48 to $3.44. Rallies surfaces TRIB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns TRIB stock?

Hedge funds tracked by Rallies that own TRIB include Renaissance Technologies and Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Trinity Biotech plc.

TRIB Key Metrics

Key financial metrics for TRIB
Metric	Value
Price	$0.59
Market Cap	$11.54M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.22%
52-Week High	$3.44
52-Week Low	$0.48
Volume	170
Avg Volume	0
Revenue (TTM)	$0
Net Income	$0
Gross Margin	0.00%

Top Hedge Funds Holding TRIB

Renaissance Technologies holds 189.05K shares of TRIB, changed -24.43% as of Dec 31, 2024.
Citadel Advisors holds 14.15K shares of TRIB, changed +0.02% as of Sep 30, 2024.

Latest TRIB News

Trinity Biotech’s Enhanced EpiCapture Test Achieves 85% AUC in 750-Sample Study — Mar 23, 2026
Trinity Biotech to Commercialize Sjögren’s Syndrome Biomarkers via NYSDOH-Approved Lab — Mar 18, 2026
Trinity Biotech Begins Brazil Launch of IFCC Gold Premier Hb9210 System — Mar 12, 2026
Trinity Biotech Reports $11.5–12.5M Q4 Revenue, CGM+ MARD Improvement — Mar 10, 2026
Trinity Biotech Secures $25M Standby Equity Line at 3% VWAP Discount — Feb 25, 2026

Recent TRIB Insider Trades

ROBERT R MCCORMICK TRIBUNE FOUNDATION sold 17.80K (~$924.52K) on Feb 18, 2004.
ROBERT R MCCORMICK TRIBUNE FOUNDATION sold 92.00K (~$4.82M) on Feb 17, 2004.
ROBERT R MCCORMICK TRIBUNE FOUNDATION sold 65.20K (~$3.39M) on Feb 13, 2004.

TRIB Analyst Consensus

TRIB analyst coverage data. Average price target: $0.00.

Common questions about TRIB

Who owns TRIB stock?: Hedge funds tracked by Rallies that own TRIB include Renaissance Technologies and Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Trinity Biotech plc.
Does Rallies show 13F holders for TRIB?: Yes. Rallies tracks hedge fund and 13F ownership data for TRIB, including fund names, share counts, latest tracked quarter, and position changes when available.
Is TRIB research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TRIB. It does not provide personalized investment advice.